⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155819 | 0.85 | — | — | |
| SCHEMBL6943100 | 0.85 | — | — | |
| SCHEMBL7505550 | 0.82 | CYP19A1 (0.44) | — | |
| SCHEMBL7505177 | 0.82 | CYP19A1 (0.44) | — | |
| SCHEMBL6940752 | 0.81 | — | — | |
| SCHEMBL7508634 | 0.79 | KMT2A (0.43) | — | |
| SCHEMBL9044355 | 0.78 | ULK1 (0.46) | — | |
| SCHEMBL7507772 | 0.78 | CYP19A1 (0.41) | — | |
| SCHEMBL9048785 | 0.78 | CYP19A1 (0.41) | — | |
| SCHEMBL7622071 | 0.78 | MEN1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| EP-1203767-A1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| JP-3113678-B2 | — | — | 2000-12-04 | — | — | JP | claimed |
| US-5646170-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-07-08 | — | — | US | claimed |
| EP-0600950-B1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1996-10-23 | — | — | EP | claimed |
| EP-0684945-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1995-12-06 | — | — | EP | claimed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0600950-A1 | AMIDE TETRAZOLE ACAT INHIBITORS. | WARNER LAMBERT CO (US) | 1994-06-15 | — | — | EP | claimed |
| WO-1993004052-A1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1203767-A1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| US-5646170-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0600950-B1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5441975-A | Anticholesterol agent | WARNER-LAMBERT COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5366987-A | Enzyme inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1993004052-A1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |